NaNotics, LLC

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
NaNotics, LLC is an U.S. biotechnology company headquartered in Marin, California, founded in 2014.
NaNotics is developing a new method of treating disease via injectable nanoparticles called NaNots, which scavenge specific circulating molecules driving disease. NaNotics is developing a NaNot set for treating cancer AND a set for treating sepsis/ARDS, the leading cause of death in COVID -19 patients – and 11 million sepsis patients annually. In cancer, NaNots target tumor-generated immune-inhibitors, which cancer cells use to defend themselves. Depleting these targets from circulation induces their migration out of the tumor microenvironment, enabling immunologic response and tumor regression that safely exceeds the performance of checkpoint inhibitors. For Covid-19 sepsis/ARDS, NaNots target key inflammatory cytokines known to drive this condition. NaNotics has completed engineering of NaNots against multiple targets, documenting efficacy in multiple disease models.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
6 NaNots: 3 inflammatory targets, 3 immune-inhibiting targets for treating solid-tumor cancer
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
All 6 of our lead candidates in preclinical development will be available for licensing.
Speaker
photo
CEO
NaNotics, LLC